Filing Flows › Comparisons › PRME vs ATRA
Prime Medicine vs Atara Biotherapeutics: PRME and ATRA compared
Prime Medicine is the larger company: $838K of revenue in its latest quarter (Q4 2025) against $630K for Atara Biotherapeutics (Q2 2026). Prime Medicine is growing faster (-62% against -96% a year earlier).
Where the money goes: PRME and ATRA
Prime Medicine (PRME) · Q4 2025
Prime Medicine, Q4 2025: revenue $838K (-62% year over year), net loss $46.1M, operating cash flow −$37.3M. The chart follows the revenue to costs, profit and cash.
Atara Biotherapeutics (ATRA) · Q2 2026
Atara Biotherapeutics, Q2 2026: revenue $630K (-96% year over year), operating margin -749.2%, net loss $4.8M, operating cash flow −$3.3M. The chart follows the revenue to costs, profit and cash.
| Prime Medicine (PRME) | Atara Biotherapeutics (ATRA) | |
|---|---|---|
| Latest quarter | Q4 2025 | Q2 2026 |
| Revenue | $838K | $630K |
| Revenue growth, Y/Y | -62% | -96% |
| Operating margin | n/m | -749.2% |
| Net earnings | −$46.1M | −$4.8M |
| Net margin | — | -767.3% |
| Operating cash flow | −$37.3M | −$3.3M |
Questions
Which is bigger, Prime Medicine or Atara Biotherapeutics?
Prime Medicine is the larger company: $838K of revenue in its latest quarter (Q4 2025) against $630K for Atara Biotherapeutics (Q2 2026).
Is Prime Medicine or Atara Biotherapeutics growing faster?
Prime Medicine is growing faster (-62% against -96% a year earlier).
More: Prime Medicine earnings · how Prime Medicine makes money · Atara Biotherapeutics earnings · how Atara Biotherapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 3, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.